Skip to main content
. 2009 Jul 20;27(24):3969–3974. doi: 10.1200/JCO.2008.21.3330

Fig 2.

Fig 2.

Overall survival according to grouped categories of response at 4 months of imatinib. CR, complete response; PR, partial response; MR, minor response; NC−, no change (0% to 10% reduction); NC+, no change (0% to 20% size increase); PD, progressive disease.